Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05323747 · ClinicalTrials.gov registry record
Prospective Evaluation of a Commercially Available Hydrogel Spacer
A clinical trial of Prostate Cancer, sponsored by BioProtect.
- Completed
- Registry status
- 20
- Enrollment target
- 2
- Study locations
NCT05323747: Completed study of Prostate Cancer, sponsored by BioProtect.
NCT05323747 is a study of Prostate Cancer that has completed, run by BioProtect. The registered enrollment target is 20 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05323747, a study of Prostate Cancer, has completed, sponsored by BioProtect.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Dosimetry efficacy evaluation of the hydrogel spacer
Primary Outcome
Assessment of rectal radiation exposure as compared between rectal dose volume histograms calculated for pre and post Hydrogel Injection
Conditions Studied
Interventions
- OTHER Observation
Study Locations (2)
California
- Western Radiation Oncology - Campbell
Nevada
- Northern Nevada Radiation Oncology - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2022-02-08 |
What the finished NCT05323747 record still lists
NCT05323747 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05323747 reports a single indexed study location in California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05323747 about?
NCT05323747 is a clinical study titled "Prospective Evaluation of a Commercially Available Hydrogel Spacer". Dosimetry efficacy evaluation of the hydrogel spacer
What is the current status of trial NCT05323747?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2020-11-20. Estimated completion is 2022-02-08.
What conditions does trial NCT05323747 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05323747?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05323747?
This trial is sponsored by BioProtect, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05323747 being conducted?
This trial has 2 study locations across California, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05323747's enrollment target sits among peer trials
20 653rd of 735 higher than 69 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI